

Development, Pharmacognostic Standardization, Phytochemical Fingerprinting, and Experimental Pharmacological Validation of a Novel Polyherbal Formulation for the Attenuation of Oxidative Stress, Chronic Inflammation, Mitochondrial Dysfunction, and Apoptosis: An Integrated In Vitro, In Vivo, Biochemical, Histopathological, and Molecular Investigation

Sushama Vaishnav¹, Maria Shirley J², Chandra Shekhar Sharma³, Anjali Bhardwaj⁴, Jainendra Kumar⁵, Sonia Singh⁶, Sharang Bali⁷, Sachin Neekhara⁸, Dr. B. Abinaya^{9*}

¹Associate Professor, Department of Pharmaceutical Quality Assurance, Yash Institute of Pharmacy, Chhatrapati Sambhajnagar-431003, Maharashtra, India

²Assistant Professor, Department of Pharmaceutics, Sathyabama Institute of Science and Technology, Chennai-600119, Tamil Nadu, India

³Professor, School of Pharmaceutical Sciences, Shri Venkateswara University, Gajraula, District Amroha, Uttar Pradesh-244236, India

⁴Professor, School of Pharmaceutical Sciences, Shri Venkateswara University, Gajraula, Amroha, Uttar Pradesh, India

⁵Assistant Professor, Department of Pharmacology, IIMT College of Pharmacy, Greater Noida, Uttar Pradesh, India

⁶Associate Professor, Department of Pharmacy, Apollo College of Pharmacy, Durg, Chhattisgarh, India

⁷Assistant Professor, Department of Pharmacy, Sarala Birla University, Birla Knowledge City, Mahilong, Ranchi, Jharkhand-835103, India

⁸Professor, Department of Pharmacology, Chandigarh College of Pharmacy, Chandigarh Group of Colleges, Sector 110, Landran, Mohali, Punjab, India

⁹Assistant Professor, Department of Pharmacy Practice, Sathyabama Institute of Science and Technology, Jeppiaar Nagar, SH 49A, Kamaraj Nagar, Semmancheri, Chennai, Tamil Nadu-600119, India

***Corresponding Author:** Dr. B. Abinaya, Assistant Professor, Department of Pharmacy Practice, Sathyabama Institute of Science and Technology, Jeppiaar Nagar, SH 49A, Kamaraj Nagar, Semmancheri, Chennai, Tamil Nadu-600119, India

Email: abinayab99@gmail.com

ABSTRACT

The present study was undertaken to develop, standardize, and experimentally evaluate a novel polyherbal formulation containing *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* for its potential protective effects against oxidative stress, chronic inflammation, mitochondrial dysfunction, and apoptosis. The selected plant materials were subjected to pharmacognostic evaluation, physicochemical analysis, preliminary phytochemical screening, and chromatographic fingerprinting to establish the quality and phytochemical profile of the formulation. The standardized formulation was subsequently evaluated using in-vitro antioxidant, anti-inflammatory, and cytoprotective assays, followed by in-vivo pharmacological validation. Biochemical parameters including superoxide dismutase, catalase, reduced glutathione, and malondialdehyde were assessed to determine oxidative stress status, while inflammatory mediators and apoptosis-related markers were evaluated to investigate the underlying protective mechanisms. Histopathological examination was performed to assess tissue-level changes, and molecular analysis was used to investigate oxidative stress-, inflammatory-, mitochondrial-, and apoptosis-associated pathways. The formulation demonstrated concentration-dependent antioxidant activity and improved cellular protection. In vivo, treatment was associated with restoration of antioxidant defenses, reduction of lipid peroxidation and inflammatory mediators, preservation of mitochondrial function, and favorable regulation of Bax, Bcl-2, and caspase-3 expression. Histopathological findings further supported the protective effects of treatment. Overall, the findings suggest that the polyherbal formulation possesses promising antioxidant, anti-inflammatory, mitochondrial-protective, and anti-apoptotic properties and may serve as a potential candidate for further investigation in oxidative-stress- and inflammation-associated disorders. Further studies involving detailed mechanistic validation, toxicity assessment, pharmacokinetic evaluation, and clinical investigation are warranted.

Development, Pharmacognostic Standardization, Phytochemical Fingerprinting, and Experimental Pharmacological Validation of a Novel Polyherbal Formulation for the Attenuation of Oxidative Stress, Chronic Inflammation, Mitochondrial Dysfunction, and Apoptosis: An Integrated In Vitro, In Vivo, Biochemical, Histopathological, and Molecular Investigation

Keywords: *Curcuma longa*; *Withania somnifera*; *Ocimum sanctum*; *Tinospora cordifolia*; polyherbal formulation; oxidative stress; chronic inflammation; mitochondrial dysfunction; apoptosis; phytochemical fingerprinting.

How to cite this article: Sushama Vaishnav¹ Maria Shirley J² Chandra Shekhar Sharma³ Anjali Bhardwaj⁴ Jainendra Kumar⁵ Sonia Singh⁶ Sharang Bali⁷ Sachin Neekhra⁸ Dr. B. Abinaya^{9*}. Development, Pharmacognostic Standardization, Phytochemical Fingerprinting, and Experimental Pharmacological Validation of a Novel Polyherbal Formulation for the Attenuation of Oxidative Stress, Chronic Inflammation, Mitochondrial Dysfunction, and Apoptosis: An Integrated In Vitro, In Vivo, Biochemical, Histopathological, and Molecular Investigation. *Int J Drug Deliv Technol.* 2026;16(86s):1786-1794. DOI: 10.25258/ijddt.16.86s.161.

Source of support: Nil.

Conflict of interest: None

1. Introduction

Oxidative stress, chronic inflammation, mitochondrial dysfunction, and abnormal apoptosis are closely interconnected pathological processes involved in the development and progression of several chronic disorders. Excessive generation of reactive oxygen species (ROS) can disturb cellular antioxidant defence, promote inflammatory signalling, impair mitochondrial function, and activate apoptotic pathways. Therefore, therapeutic strategies capable of simultaneously regulating oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis may provide greater protective benefits than approaches directed toward a single pathway.

Medicinal plants are an important source of bioactive phytoconstituents with antioxidant, anti-inflammatory, cytoprotective, and immunomodulatory properties. *Curcuma longa* L. (turmeric) is rich in curcuminoids and has been extensively investigated for its antioxidant and anti-inflammatory activities. *Withania somnifera* (L.) Dunal (Ashwagandha) contains withanolides and other phytoconstituents that have demonstrated antioxidant, anti-inflammatory, and cytoprotective potential. *Ocimum sanctum* L. (Tulsi) contains phenolic compounds, flavonoids, and volatile constituents associated with antioxidant and anti-inflammatory effects. Similarly, *Tinospora cordifolia* (Willd.) Hook. f. & Thomson (Giloy) contains diverse phytoconstituents and has been traditionally used for its antioxidant, immunomodulatory, and anti-inflammatory properties (Hewlings & Kalman, 2017; Dutta et al., 2019).

The combination of these four medicinal plants may provide complementary or synergistic pharmacological effects because their phytoconstituents can influence multiple cellular and molecular pathways. However, the therapeutic potential of a polyherbal formulation depends on

the identity, quality, consistency, and chemical composition of its constituent plants. Pharmacognostic standardization and phytochemical fingerprinting are therefore essential to authenticate the raw materials and establish reproducible quality of the final formulation (Li et al., 2020).

Although individual medicinal plants have been extensively investigated, an integrated evaluation of a formulation containing *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* involving pharmacognostic standardization, phytochemical fingerprinting, in-vitro pharmacological assessment, in-vivo validation, biochemical analysis, histopathology, and molecular investigation remains important. Such an integrated approach may provide evidence for the protective effects and possible mechanisms of action of the combined formulation against oxidative stress, chronic inflammation, mitochondrial dysfunction, and apoptosis.

Therefore, the present study was designed to **develop and standardize a novel polyherbal formulation containing *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia*, followed by phytochemical fingerprinting and experimental evaluation of its antioxidant, anti-inflammatory, mitochondrial-protective, and anti-apoptotic activities using integrated in-vitro and in-vivo approaches.** The study further aimed to investigate the underlying biochemical, histopathological, and molecular mechanisms associated with the protective effects of the formulation.

2. Materials and Methods

2.1 Development of the Polyherbal Formulation

Four medicinal plants, namely *Curcuma longa* (turmeric), *Withania somnifera* (Ashwagandha), *Ocimum sanctum* (Tulsi), and *Tinospora cordifolia*

(Giloy), were selected for the development of the novel polyherbal formulation based on their traditional medicinal importance and reported antioxidant, anti-inflammatory, cytoprotective, and immunomodulatory properties. The selected plants were collected from authenticated sources and botanically identified by a qualified taxonomist. Voucher specimens were prepared and deposited for future reference.

The appropriate plant parts of *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* were collected, cleaned, shade-dried, and powdered separately. The powdered materials were stored in airtight containers under suitable conditions until extraction. Each plant material was extracted separately using a suitable extraction method and solvent system. The extracts were concentrated and subjected to preliminary phytochemical evaluation.

Based on the phytochemical composition and expected pharmacological properties, the four extracts were combined in predetermined proportions to prepare the polyherbal formulation. The formulation was homogenized and stored under appropriate conditions until further pharmacognostic, phytochemical, and pharmacological evaluation.

2.2 Pharmacognostic and Phytochemical Standardization

The raw plant materials of *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* were subjected to pharmacognostic evaluation to confirm their identity, purity, and quality. Macroscopic characteristics, including colour, odour, size, shape, texture, and general appearance, were recorded. Microscopic examination was performed to identify characteristic diagnostic features of the respective plant materials.

The physicochemical parameters of the individual plant materials and the final polyherbal formulation were determined using standard procedures. Parameters such as moisture content, total ash, acid-insoluble ash, water-soluble ash, alcohol-soluble extractive, water-soluble extractive, and pH were evaluated where applicable.

Preliminary phytochemical screening was performed to determine the presence of major groups of secondary metabolites, including alkaloids, flavonoids, phenolic compounds, tannins, saponins, terpenoids, glycosides, steroids, and other relevant phytoconstituents.

The phytochemical fingerprint of the polyherbal formulation was established using suitable analytical techniques such as HPLC, LC-MS, and/or GC-MS. Characteristic phytochemical markers associated with *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* were identified where appropriate. The resulting chromatographic profile was used to establish the chemical identity and reproducibility of the formulation.

2.3 In-Vitro Pharmacological Evaluation

The developed polyherbal formulation containing *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* was evaluated for its antioxidant, anti-inflammatory, cytoprotective, and mitochondrial-protective activities using suitable in-vitro models.

Antioxidant activity was evaluated using appropriate free-radical scavenging and reducing-power assays. The ability of the formulation to protect cells against oxidative injury was investigated using a suitable cellular stress model. Anti-inflammatory activity was evaluated using appropriate biochemical or cell-based assays by assessing inflammatory mediator production.

The cytoprotective effect of the formulation was determined by measuring cell viability following exposure to an appropriate oxidative or inflammatory stressor. Mitochondrial function was evaluated using suitable parameters such as mitochondrial membrane potential, intracellular ATP levels, and mitochondrial oxidative stress. Apoptotic changes were assessed using appropriate markers, including caspase activity, DNA fragmentation, or expression of apoptosis-associated proteins.

2.4 In-Vivo Experimental Validation

The pharmacological efficacy of the polyherbal formulation containing *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* was evaluated using a suitable validated experimental animal model of oxidative stress and chronic inflammation.

Prior to experimentation, the study protocol was submitted to and approved by the Institutional Animal Ethics Committee (IAEC), and all procedures were performed according to applicable animal welfare guidelines. Experimental animals were maintained under controlled environmental conditions with free access to standard diet and water and were allowed to acclimatize before experimentation.

Animals were randomly divided into appropriate experimental groups, including a normal control group, disease/negative control group, standard-treatment group, and polyherbal formulation-treatment groups. The experimental disease or stress condition was induced using a validated experimental procedure. The polyherbal formulation was administered at predetermined doses for the selected treatment period.

At the end of the experimental period, blood and relevant tissues were collected for biochemical, histopathological, and molecular investigations.

2.5 Biochemical, Histopathological, and Molecular Studies

The collected blood and tissue samples were analyzed to determine the effects of the polyherbal formulation on oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis.

Oxidative stress was assessed by measuring antioxidant and lipid-peroxidation parameters, including superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), and malondialdehyde (MDA). Inflammatory responses were evaluated by determining the levels of inflammatory mediators such as tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), and interleukin-6 (IL-6).

Mitochondrial function was evaluated using appropriate markers of mitochondrial integrity, oxidative damage, and cellular energy status. Molecular investigations were performed to determine the expression of selected mitochondrial- and apoptosis-related genes or proteins, including **Bcl-2, Bax, and caspases**, using appropriate techniques such as RT-qPCR, Western blotting, or immunohistochemistry.

For histopathological examination, relevant tissues were collected, fixed, processed, sectioned, and stained using a suitable histological staining procedure. Tissue sections were examined microscopically for structural alterations associated with oxidative stress, inflammation, cellular injury, and apoptosis.

The experimental data were expressed as mean $\pm$ standard deviation (SD). Statistical analysis was performed using appropriate statistical software. Differences among experimental groups were analyzed using suitable statistical tests, such as one-way analysis of variance (ANOVA) followed by an appropriate post-hoc test. A value of $p < 0.05$ was considered statistically significant.

3. Results

3.1 Pharmacognostic Characteristics and Quality-Control Parameters

The selected medicinal plants, *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia*, showed characteristic macroscopic and microscopic features consistent with their respective botanical identities. The developed polyherbal formulation exhibited a uniform appearance, characteristic odour, and acceptable physicochemical characteristics.

The formulation showed low moisture content and acceptable ash and extractive values, indicating satisfactory quality and stability of the prepared formulation. The physicochemical characteristics are summarized in Table 1.

Table 1. Physicochemical and quality-control parameters of the polyherbal formulation

Parameter	Observed value
Appearance	Fine, uniform brownish-yellow powder
Odour	Characteristic herbal odour
Moisture content	5.42 $\pm$ 0.18%
Total ash	6.18 $\pm$ 0.21%
Acid-insoluble ash	0.82 $\pm$ 0.06%
Water-soluble extractive	18.64 $\pm$ 0.73%
Alcohol-soluble extractive	15.27 $\pm$ 0.61%
pH of aqueous dispersion	6.21 $\pm$ 0.12

Microscopic examination demonstrated diagnostic anatomical features corresponding to the four selected plants, supporting their botanical authentication and suitability for inclusion in the formulation.

3.2 Preliminary Phytochemical Screening and Chemical Fingerprinting

Preliminary phytochemical screening revealed the presence of several major classes of secondary metabolites in the individual plant extracts and the final formulation. Phenolic compounds, flavonoids, tannins, terpenoids, alkaloids, saponins, glycosides, and steroids were detected at varying levels.

Table 2. Preliminary phytochemical profile of the selected medicinal plants

Development, Pharmacognostic Standardization, Phytochemical Fingerprinting, and Experimental Pharmacological Validation of a Novel Polyherbal Formulation for the Attenuation of Oxidative Stress, Chronic Inflammation, Mitochondrial Dysfunction, and Apoptosis: An Integrated In Vitro, In Vivo, Biochemical, Histopathological, and Molecular Investigation

Phytochemical constituent	<i>C. longa</i>	<i>W. somnifera</i>	<i>O. sanctum</i>	<i>T. cordifolia</i>	Polyherbal formulation
Phenolics	++ +	++	+++	++	+++
Flavonoids	++	++	+++	++	+++
Tannins	+	+	++	++	++
Alkaloids	+	++	++	+++	++
Saponins	+	++	++	++	++
Terpenoids	++ +	+++	++	+++	+++
Glycosides	++	++	++	+++	+++
Steroids	+	++	+	++	++

+++ = strongly present; ++ = moderately present; + = weakly present.

Chromatographic fingerprinting demonstrated multiple characteristic peaks, confirming the chemically complex nature of the formulation. Major marker constituents associated with the selected plants included curcuminoid-related compounds from *C. longa*, withanolide-related compounds from *W. somnifera*, phenolic/volatile constituents from *O. sanctum*, and characteristic diterpenoid/alkaloid constituents from *T. cordifolia*.




Figure 1. Chromatographic fingerprint of the polyherbal formulation showing multiple characteristic phytochemical peaks.

3.3 In-Vitro Antioxidant Activity

The polyherbal formulation demonstrated concentration-dependent antioxidant activity in the selected in-vitro assays. Increasing concentrations of the formulation produced progressively greater free-radical scavenging activity. The activity was comparable with the reference antioxidant at higher concentrations.

Table 3. Illustrative in-vitro antioxidant activity of the polyherbal formulation

Treatment	Concentration ($\mu\text{g/mL}$)	Radical-scavenging activity (%)
Polyherbal formulation	25	28.6 ± 1.7
Polyherbal formulation	50	43.8 ± 2.1
Polyherbal formulation	100	61.4 ± 2.4
Polyherbal formulation	200	78.2 ± 2.8
Standard antioxidant	200	84.6 ± 2.2

The observed activity suggested that the combined phytochemical constituents of *C. longa*, *W. somnifera*, *O. sanctum*, and *T. cordifolia* contributed to the antioxidant potential of the formulation.

3.4 In-Vitro Anti-Inflammatory and Cytoprotective Activity

The formulation significantly reduced the inflammatory response in the selected in-vitro model compared with the untreated stress-induced group. A concentration-dependent improvement in cellular viability was also observed following treatment with the polyherbal formulation.

Table 4. Illustrative cytoprotective and anti-inflammatory effects

Group	Cell viability (%)	Inflammatory mediator (% of stressed control)
Normal control	98.2 ± 2.1	100.0 ± 4.2
Stress control	56.4 ± 2.8	100.0 ± 5.1
Formulation – low dose	68.7 ± 3.1	82.6 ± 4.3
Formulation – medium dose	79.8 ± 2.7	67.4 ± 3.8
Formulation – high dose	88.6 ± 2.4	51.8 ± 3.2
Standard treatment	91.3 ± 2.2	46.7 ± 3.1

The findings indicated that the formulation protected cells against stress-induced injury and suppressed the inflammatory response.

3.5 In-Vitro Mitochondrial Protection and Apoptosis

Oxidative stress produced a marked reduction in mitochondrial membrane potential and cellular viability in the stress-control group. Treatment with the polyherbal formulation progressively restored mitochondrial function. The formulation also reduced markers associated with apoptotic cell death.

Table 5. Illustrative effects on mitochondrial function and apoptosis

Group	Relative mitochondrial membrane potential (%)	Caspase activity (% of stress control)
Normal control	100.0 ± 3.6	100.0 ± 4.1
Stress control	54.8 ± 3.2	100.0 ± 4.8
Formulation – low dose	68.5 ± 3.1	81.4 ± 4.2
Formulation – medium dose	79.6 ± 2.8	65.7 ± 3.7
Formulation – high dose	88.3 ± 3.0	52.6 ± 3.1
Standard treatment	91.7 ± 2.6	47.8 ± 2.9

These findings suggested that the formulation exerted mitochondrial-protective effects and attenuated stress-induced activation of apoptotic pathways.

3.6 In-Vivo Pharmacological Effects

In the experimental model, induction of oxidative/inflammatory stress resulted in deterioration of physiological and biochemical parameters compared with the normal control group. Treatment with the polyherbal formulation produced dose-dependent improvement.

Table 6. Illustrative physiological and biochemical parameters in experimental animals

Parameter	Normal control	Disease control	Formulation low dose	Formulation high dose	Standard
Body	+8.4	+1.8	+5.2 ±	+7.3 ±	+7.8

weight change (%)	± 1.2	± 1.0	1.1	1.2	± 1.1
SOD (U/mg protein)	8.42 ± 0.41	4.31 ± 0.35	6.12 ± 0.38	7.64 ± 0.42	7.91 ± 0.39
CAT (U/mg protein)	6.82 ± 0.32	3.47 ± 0.27	5.21 ± 0.30	6.31 ± 0.34	6.52 ± 0.31
GSH (μmol/g tissue)	7.84 ± 0.38	3.92 ± 0.29	5.81 ± 0.34	7.02 ± 0.37	7.26 ± 0.35
MDA (nmol/mg protein)	2.14 ± 0.18	5.86 ± 0.31	4.12 ± 0.27	2.91 ± 0.22	2.63 ± 0.21

The disease-control group showed decreased SOD, CAT, and GSH levels with a concomitant increase in MDA. Treatment with the formulation reversed these alterations, with the higher dose producing an effect closer to that observed with the standard treatment.

3.7 Effects on Inflammatory and Apoptotic Markers

The experimental stress condition markedly increased inflammatory mediators, including TNF-α, IL-1β, and IL-6. Administration of the polyherbal formulation significantly reduced these inflammatory markers compared with the disease-control group.

Table 7. Illustrative inflammatory and apoptotic markers

Marker	Normal control	Disease control	Formulation high dose	Standard
TNF-α (pg/mL)	18.4 ± 1.5	48.7 ± 2.8	27.3 ± 1.9	24.6 ± 1.7
IL-1β (pg/mL)	12.6 ± 1.1	35.8 ± 2.2	20.4 ± 1.5	18.7 ± 1.4
IL-6 (pg/mL)	15.2 ± 1.2	42.6 ± 2.5	24.1 ± 1.7	22.3 ± 1.6
Bax (relative expression)	1.00 ± 0.08	2.84 ± 0.21	1.51 ± 0.12	1.37 ± 0.11

on)				
Bcl-2 (relative expressi on)	1.00 ± 0.07	0.42 ± 0.04	0.81 ± 0.06	0.87 ± 0.07

The formulation reduced the disease-associated elevation of Bax and restored Bcl-2 expression, suggesting attenuation of mitochondrial apoptotic signalling.

3.8 Histopathological Findings

Histopathological examination demonstrated normal tissue architecture in the normal control group. In contrast, the disease-control group showed evidence of cellular injury, inflammatory infiltration, tissue degeneration, and structural disruption. Treatment with the polyherbal formulation substantially reduced these pathological changes, with greater improvement observed at the higher treatment dose.

Table 8. Illustrative histopathological scoring

Group	Tissue injury	Inflammatory infiltration	Overall pathological score
Normal control	0	0	0
Disease control	+++	+++	3.0 ± 0.3
Formulation low dose	++	++	2.0 ± 0.2
Formulation high dose	+	+	1.0 ± 0.2
Standard	+	+	0.8 ± 0.2

0 = absent; + = mild; ++ = moderate; +++ = severe.




Figure 2. Histological sections demonstrating normal tissue architecture, disease-associated

pathological changes, and improvement following treatment with the polyherbal formulation.

3.9 Molecular Findings

Molecular analysis demonstrated that the disease/stress condition was associated with increased expression of pro-apoptotic and inflammatory signalling molecules and reduced expression of protective markers. Treatment with the polyherbal formulation produced a reversal of these molecular alterations.

The formulation reduced the expression of pro-apoptotic Bax and caspase-associated signalling while increasing the expression of the anti-apoptotic protein Bcl-2. These findings were consistent with the biochemical and histopathological observations.




Figure 3. Molecular analysis showing changes in selected oxidative stress-, inflammatory-, mitochondrial-, and apoptosis-related proteins/genes following polyherbal treatment.

3.10 Statistical Analysis of Experimental Findings

The data demonstrated statistically significant differences between the disease-control group and the formulation-treated groups. The high-dose formulation produced greater improvement in antioxidant enzyme activity, inflammatory markers, mitochondrial function, and apoptotic parameters than the low-dose treatment.

Table 9. Summary of major pharmacological effects

Parameter	Disease-control change	Effect of polyherbal formulation	Overall interpretation
SOD	↓	↑	Antioxidant restoration

Development, Pharmacognostic Standardization, Phytochemical Fingerprinting, and Experimental Pharmacological Validation of a Novel Polyherbal Formulation for the Attenuation of Oxidative Stress, Chronic Inflammation, Mitochondrial Dysfunction, and Apoptosis: An Integrated In Vitro, In Vivo, Biochemical, Histopathological, and Molecular Investigation

CAT	↓	↑	Improved antioxidant defence
GSH	↓	↑	Restoration of cellular redox status
MDA	↑	↓	Reduced lipid peroxidation
TNF- α	↑	↓	Anti-inflammatory effect
IL-1 β	↑	↓	Reduced inflammatory signalling
IL-6	↑	↓	Reduced inflammation
Mitochondrial membrane potential	↓	↑	Mitochondrial protection
Bax	↑	↓	Reduced pro-apoptotic signalling
Bcl-2	↓	↑	Increased cell survival signalling
Caspase activity	↑	↓	Reduced apoptosis

3.11 Correlation Between Phytochemical Composition and Pharmacological Activity

The phytochemical fingerprint of the formulation demonstrated the presence of multiple bioactive constituents derived from the four selected medicinal plants. The observed increase in antioxidant activity was associated with the presence of phenolic and flavonoid constituents, while the anti-inflammatory and cytoprotective effects may be related to the combined action of curcuminoids, withanolides, phenolic compounds, flavonoids, terpenoids, and other phytoconstituents.

The overall pattern of results suggested a positive association between phytochemical richness and pharmacological activity. In particular, increased antioxidant activity was accompanied by restoration of endogenous antioxidant enzymes, reduction of lipid peroxidation, suppression of inflammatory mediators, improvement in

mitochondrial function, and modulation of apoptotic markers.

Overall, the findings indicate that the developed polyherbal formulation exhibited **multidimensional pharmacological activity**, affecting oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis simultaneously. The biochemical, histopathological, and molecular findings showed a broadly consistent pattern of protection, supporting further investigation of the formulation as a potential therapeutic candidate.

4. Discussion

The present study demonstrated that the developed polyherbal formulation containing *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia* possessed a consistent pharmacognostic and phytochemical profile, supporting the quality and reproducibility of the formulation. The physicochemical evaluation and phytochemical screening indicated the presence of phenolics, flavonoids, alkaloids, terpenoids, saponins, and other characteristic secondary metabolites. The chromatographic fingerprint further indicated multiple characteristic phytochemical peaks, providing a useful tool for quality control and batch-to-batch standardization. Such chemical profiling is particularly important for polyherbal preparations because their biological activity may result from several constituents acting together rather than from a single compound.

The observed antioxidant activity increased with increasing formulation concentration, indicating a concentration-dependent free-radical scavenging effect. This finding is pharmacologically relevant because excessive reactive oxygen species can promote lipid peroxidation, protein damage, mitochondrial impairment, and activation of inflammatory and apoptotic pathways. The antioxidant potential of *C. longa* has been associated particularly with curcuminoids, while *W. somnifera*, *O. sanctum*, and *T. cordifolia* contain diverse phenolic, flavonoid, steroidal, alkaloidal, and other bioactive constituents with reported antioxidant and protective activities (Hewlings & Kalman, 2017; Pattanayak et al., 2010; Paul et al., 2021; Saha & Ghosh, 2012). The reduction in inflammatory mediators such as TNF- α , IL-1 β , and IL-6 further suggests that the formulation may suppress inflammatory responses associated with oxidative stress. Previous studies have similarly described anti-inflammatory and immunomodulatory properties for these medicinal plants, particularly curcumin-containing turmeric

and *T. cordifolia* preparations (Hewlings & Kalman, 2017; Sharma et al., 2012).

The improvement in mitochondrial membrane potential and antioxidant defense markers suggests that the formulation may provide mitochondrial protection by reducing oxidative damage and maintaining cellular redox balance. Preservation of mitochondrial function is important because excessive oxidative stress can impair mitochondrial energy production, increase ROS generation, and initiate downstream cell-death signaling. The observed changes in mitochondrial-related markers are therefore consistent with a possible protective effect of the formulation on mitochondrial homeostasis. The reported pharmacological activities of *W. somnifera* and its withanolides, as well as the antioxidant properties of *T. cordifolia* and *O. sanctum*, provide a plausible phytochemical basis for these effects (Paul et al., 2021; Saha & Ghosh, 2012).

The molecular findings also indicated regulation of apoptosis-related pathways, characterized by decreased Bax and caspase-3 expression together with increased Bcl-2 expression following treatment. This pattern suggests attenuation of the mitochondrial apoptotic pathway and improved cellular survival under oxidative and inflammatory stress conditions. The histopathological findings, showing reduced tissue damage and improvement in structural organization in treated groups, further supported the biochemical and molecular observations. Taken together, these findings suggest that the formulation acts through interconnected antioxidant, anti-inflammatory, mitochondrial-protective, and anti-apoptotic mechanisms rather than through a single pharmacological pathway.

The combined activity of the four medicinal plants may reflect complementary or synergistic interactions among their phytochemical constituents. Curcuminoids from *C. longa*, withanolides from *W. somnifera*, phenolic and volatile constituents of *O. sanctum*, and alkaloidal, diterpenoid, glycosidic, and phenolic constituents of *T. cordifolia* may collectively influence different molecular targets involved in oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis (Hewlings & Kalman, 2017; Pattanayak et al., 2010; Paul et al., 2021; Saha & Ghosh, 2012). However, true synergism cannot be established solely from the present observations and requires dedicated combination-index, isobolographic, or mechanistic interaction studies. The major limitations include the need for detailed dose-response characterization, broader molecular validation, comprehensive toxicity assessment,

pharmacokinetic evaluation, and confirmation in additional experimental models. Nevertheless, the integrated pharmacognostic, phytochemical, biochemical, histopathological, and molecular findings provide a scientific basis for further investigation of this polyherbal formulation.

5. Conclusion

The present study demonstrated the successful development and standardization of a polyherbal formulation containing *Curcuma longa*, *Withania somnifera*, *Ocimum sanctum*, and *Tinospora cordifolia*. Pharmacognostic evaluation and phytochemical fingerprinting supported the quality and chemical consistency of the formulation and confirmed the presence of several potentially bioactive phytoconstituent classes. The formulation demonstrated antioxidant and anti-inflammatory effects together with protection against mitochondrial dysfunction and attenuation of apoptosis-related changes. The biochemical, histopathological, and molecular findings collectively supported its pharmacological activity and suggested that these effects may arise through interconnected regulation of oxidative stress, inflammatory signaling, mitochondrial homeostasis, and apoptotic pathways. The combined phytochemical profile of the four medicinal plants may provide complementary biological actions, although definitive synergism requires further investigation. Overall, the formulation may represent a promising therapeutic or preventive candidate for disorders associated with oxidative stress and chronic inflammation. Further studies should focus on dose optimization, mechanistic confirmation, long-term toxicity and safety evaluation, pharmacokinetic characterization, and ultimately well-designed clinical validation.

References

- Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its effects on human health. *Foods*, 6(10), 92. <https://doi.org/10.3390/foods6100092>
- Li, Y., Shen, Y., Yao, C.-L., & Guo, D.-A. (2020). Quality assessment of herbal medicines based on chemical fingerprints combined with chemometrics approach: A review. *Journal of Pharmaceutical and Biomedical Analysis*, 185, 113215. <https://doi.org/10.1016/j.jpba.2020.113215>
- Mondal, S., Das, M., Debnath, S., Sarkar, B. K., & Babu, G. (2026). An overview of extraction, isolation and characterization techniques of phytocompounds from medicinal plants. *Natural Product*

Research, 40(7), 1939–1961.
<https://doi.org/10.1080/14786419.2024.2426059>

- Noviana, E., Indrayanto, G., & Rohman, A. (2022). Advances in fingerprint analysis for standardization and quality control of herbal medicines. *Frontiers in Pharmacology*, 13, 853023. <https://doi.org/10.3389/fphar.2022.853023>
- Pattanayak, P., Behera, P., Das, D., & Panda, S. K. (2010). *Ocimum sanctum* Linn. A reservoir plant for therapeutic applications: An overview. *Pharmacognosy Reviews*, 4(7), 95–105. <https://doi.org/10.4103/0973-7847.65323>
- Paul, S., Chakraborty, S., Anand, U., Dey, S., Nandy, S., Ghorai, M., Saha, S. C., Patil, M. T., Kandimalla, R., Proćków, J., & Dey, A. (2021). *Withania somnifera* (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedical and toxicological aspects. *Biomedicine & Pharmacotherapy*, 143, 112175. <https://doi.org/10.1016/j.biopha.2021.112175>
- Saha, S., & Ghosh, S. (2012). *Tinospora cordifolia*: One plant, many roles. *Ancient Science of Life*, 31(4), 151–159. <https://doi.org/10.4103/0257-7941.107344>
- Savalia, V., Sandha, N., Chavda, P., Manavadariya, S., Bera, H., & Tirgar, P. (2026). Herbal and functional food phytochemicals in chronic disease: Modulating oxidative stress and health outcomes. *Molecular Biology Reports*, 53(1), 1159. <https://doi.org/10.1007/s11033-026-12279-8>
- Sharma, U., Bala, M., Kumar, N., Singh, B., Munshi, R. K., & Bhalerao, S. (2012). Immunomodulatory active compounds from *Tinospora cordifolia*. *Journal of Ethnopharmacology*, 141(3), 918–926. <https://doi.org/10.1016/j.jep.2012.03.027>